Pacira BioSciences Reports Strong Q1, $50M Buyback Amidst Proxy Battle, Urges Shareholder Vote

summarizeSummary

Pacira BioSciences released definitive additional proxy materials, highlighting strong first-quarter 2026 financial results and a significant $50 million share repurchase program, while urging shareholders to vote for its nominees in the ongoing proxy contest against DOMA Perpetual.

check_boxKey Events

• Proxy Battle Update

  Pacira mailed a letter to stockholders, urging them to vote "FOR" its highly qualified director nominees on the BLUE proxy card and "AGAINST" DOMA Perpetual's candidates at the June 9, 2026 Annual Meeting.

• Strong Q1 2026 Financial Results

  The company reported $177 million in revenue for Q1 2026, representing a 5% increase year-over-year and exceeding consensus estimates, alongside $40.2 million in Adjusted EBITDA.

• Significant Share Repurchase

  Pacira executed an additional $50 million in share repurchases during Q1 2026, resulting in the retirement of approximately 2.2 million shares of common stock.

• Product Growth

  EXPAREL growth was reinvigorated, ZILRETTA sales increased by 15%, and iovera° sales grew by 21% year-over-year in Q1 2026.

auto_awesomeAnalysis

This DEFA14A filing serves as a critical communication in Pacira's ongoing proxy battle with activist investor DOMA Perpetual. The company is leveraging its strong Q1 2026 financial performance, including exceeding revenue consensus and robust product sales growth, to bolster its argument for current management and strategy. The announcement of a substantial $50 million share repurchase in Q1, which retired approximately 2.2 million shares, demonstrates a significant commitment to returning capital to shareholders and is a strong counter-argument against DOMA's criticisms. Investors should view this as a clear signal of management's confidence and a strategic move to secure shareholder support ahead of the June 9th Annual Meeting. The outcome of this proxy contest will significantly influence the company's future strategic direction and leadership.